CSBR (Champions Oncology) Earnings Power Value (EPV): $0.84 (As of Jan26)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $6.08
GF Value $6.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Earnings Power Value (EPV)?

Champions Oncology CSBR -0.98% 64 Earnings Power Value (EPV) is $0.84 as of Jan26. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review.

As of Jan26, Champions Oncology's earnings power value is $0.84. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is -622.69

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Champions Oncology  (NAS:CSBR) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Champions Oncology Earnings Power Value (EPV) Related Terms


Champions Oncology Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Earnings Power Value (EPV) Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.94 0.18 0.33 -0.95 0.60

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 0.60 0.77 0.83 0.84

CSBR vs ANVS, HYFT, GANX: Earnings Power Value (EPV) Comparison

For the Biotechnology subindustry, Champions Oncology's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology Earnings Power Value (EPV) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Earnings Power Value (EPV) falls into.


CSBR
64GF Score
Champions Oncology Inc CSBR
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Champions Oncology's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 53.25
DDA 1.75
Operating Margin % -3.48
SGA * 25% 4.30
Tax Rate % 3.30
Maintenance Capex 1.55
Cash and Cash Equivalents 7.13
Short-Term Debt 1.53
Long-Term Debt 3.37
Shares Outstanding (Diluted) 13.89

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -3.48%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $53.25 Mil, Average Operating Margin = -3.48%, Average Adjusted SGA = 4.30,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 53.25 * -3.48% +4.30 = $2.452763395 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 3.30%, and "Normalized" EBIT = $2.452763395 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 2.452763395 * ( 1 - 3.30% ) = $2.3718957858669 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 1.75 * 0.5 * 3.30% = $0.028812483 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 2.3718957858669 + 0.028812483 = $2.4007082688668 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Champions Oncology's Average Maintenance CAPEX = $1.55 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Champions Oncology's current cash and cash equivalent = $7.13 Mil.
Champions Oncology's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 3.37 + 1.53 = $4.894 Mil.
Champions Oncology's current Shares Outstanding (Diluted Average) = 13.89 Mil.

Champions Oncology's Earnings Power Value (EPV) for Jan26 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 2.4007082688668 - 1.55)/ 9%+7.13-4.894 )/13.89
=0.84

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( 0.84129703148976-6.08 )/0.84129703148976
= -622.69%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of $0.84 mean?
Champions Oncology (CSBR) has a Earnings Power Value (EPV) of $0.84 as of Jan26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Earnings Power Value (EPV) too high?
Champions Oncology's current Earnings Power Value (EPV) is $0.84. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Earnings Power Value (EPV) compare to ANVS and HYFT?
Champions Oncology's Earnings Power Value (EPV) of $0.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Champions Oncology and its competitors. Champions Oncology's current Earnings Power Value (EPV) is $0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.08 — trading 8.2% below its estimated fair value. The current Earnings Power Value (EPV) is $0.84. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Earnings Power Value (EPV) is $0.84 as of Jan26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.08 is trading 8.2% below its estimated GF Value™ of $6.62. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • Earnings Power Value (EPV): $0.84
  • GF Value™: $6.62 vs. price of $6.08 (8.2% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.08
Price
$6.62
GF Value